Overview

Useful For

Confirmation and differentiation of HIV-1 and HIV-2 antibodies in plasma specimens from prenatal patients who show reactive results with third- (HIV-1/-2 antibody only) and fourth-generation (HIV antigen and antibody) HIV serologic assays

This test is not useful as a screening test for HIV infection in symptomatic or asymptomatic individuals. It is not to be used as a screening or confirmatory test for blood donor specimens.

Reflex Tests

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Reporting Name</th>
<th>Available Separately</th>
<th>Always Performed</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIQNP</td>
<td>HIV-1 RNA Detect/Quant Prenatal, P</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Testing Algorithm

This test is for confirmation and differentiation of HIV-1 and HIV-2 antibodies. If the following result types are obtained then prenatal HIV-1 RNA detection and quantification, will be performed at an additional charge:

- HIV-1 and HIV-2 both negative
- Indeterminate for HIV-1 and negative for HIV-2
- Negative for HIV-1 and indeterminate for HIV-2
- HIV-1 and HIV-2 both indeterminate

The following algorithms are available in Special Instructions:

- HIV Prenatal Testing Algorithm, Including Follow-up of Reactive Rapid Serologic Test Results
- HIV Testing Algorithm (Fourth-Generation Screening Assay), Including Neonatal Testing and Follow-up of Reactive Rapid Serologic Test Results

Special Instructions

- HIV Testing Algorithm (Fourth-Generation Screening Assay), Including Follow-up of Reactive Rapid Serologic Test Results
- HIV Prenatal Testing Algorithm, Including Follow-up of Reactive Rapid Serologic Test Results

Method Name

Rapid Immunochromatographic Assay

NY State Available

Yes

Specimen

Document generated July 2, 2020 at 3:19am CDT
**Specimen Type**

Plasma

**Advisory Information**

1. Except for pregnant patients who were reactive by the Determine HIV-1/-2 Ag/Ab Combo rapid point-of-care test on serum or plasma (but not whole blood), this test is not suitable for follow-up testing of patients with reactive results from any rapid HIV tests, regardless of the specimen type tested. These patients should be tested subsequently with laboratory-based HIV antigen and antibody combination immunoassays, such as HIVSP / HIV Antigen and Antibody Prenatal Routine Screen, Plasma, per the latest CDC recommended HIV testing algorithm.

2. If specimens are autopsy or cadaver blood sources, the proper FDA-licensed assay is HV1CD / HIV-1 and HIV-2 Antibodies for Cadaveric or Hemolyzed Specimens, Serum.

3. **New York State clients**: This test should not be requested for maternal/newborn HIV screening on specimens originating in New York State, due to state regulatory requirements for expedited result reporting.

**Necessary Information**

Date of collection is required.

**Specimen Required**

**Supplies**: Aliquot Tube, 5 mL (T465)

**Collection Container/Tube**: Lavender top (EDTA)

**Submission Container/Tube**: Plastic vial

**Specimen Volume**: 1 mL

**Collection Instructions**:

1. Centrifuge blood collection tube per collection tube manufacturer's instructions (eg, centrifuge and aliquot within 2 hours of collection for BD Vacutainer tubes).

2. Aliquot plasma into plastic vial.

**Specimen Minimum Volume**

0.8 mL

**Reject Due To**

<table>
<thead>
<tr>
<th>Problem</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross hemolysis</td>
<td>OK</td>
</tr>
<tr>
<td>Gross lipemia</td>
<td>OK</td>
</tr>
<tr>
<td>Gross icterus</td>
<td>OK</td>
</tr>
</tbody>
</table>

**Specimen Stability Information**

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Temperature</th>
<th>Time</th>
<th>Special Container</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma</td>
<td>Frozen (preferred)</td>
<td>30 days</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Refrigerated</td>
<td>6 days</td>
<td></td>
</tr>
</tbody>
</table>
Clinical and Interpretive

Clinical Information

AIDS is caused by 2 known types of HIV. HIV type 1 (HIV-1) is found in patients with AIDS or AIDS-related complex, and in asymptomatic infected individuals at high risk for AIDS. The virus is transmitted by sexual contact, by exposure to infected blood or blood products, or from an infected mother to her fetus or infant. HIV type 2 (HIV-2) infection is endemic only in West Africa, and it has been identified in individuals who had sexual relations with individuals from that geographic region. HIV-2 is similar to HIV-1 in viral morphology, overall genomic structure, and its ability to cause AIDS.

Antibodies against HIV-1 and HIV-2 are usually not detectable until 6 to 12 weeks following exposure and are almost always detectable by 12 months. They may fall to undetectable levels (ie, seroreversion) in the terminal stage of AIDS when the patient's immune system is severely depressed.

Routine serologic screening of patients at risk for HIV-1 or HIV-2 infection usually begins with a HIV-1/-2 antigen and/or antibody screening test, which may be performed by various FDA-approved assay methods, including rapid HIV antibody tests, enzyme immunoassays, and chemiluminescent immunoassays. In testing algorithms that begin with these methods, supplemental or confirmatory testing should be requested only for specimens that are repeatedly reactive by these methods according to assay manufacturers' instructions for use.

Reference Values

Negative

Interpretation

Negative results for both HIV-1 and HIV-2 antibodies usually indicate the absence of HIV-1 and HIV-2 infection. However, in patients with reactive initial combined HIV-1/-2 antigen and antibody test results, such negative results do not rule-out acute or early HIV infection. In this situation, the HIQNP / HIV-1 RNA Detection and Quantification, Prenatal, Plasma reflex test will be performed. For patients at risk for HIV-2 infection (eg, having lived in West Africa or have sexual partners from West Africa), testing for HIV-2 DNA/RNA (FHV2Q / HIV-2 DNA/RNA Qualitative Real-Time PCR) is recommended.

Positive HIV-1 antibody but negative HIV-2 antibody results indicates the presence of HIV-1 infection. Together with reactive initial combined HIV-1/-2 antigen and antibody test results, individuals with such results are presumed to have HIV-1 infection. Verification of a first-time positive test result is recommended for the diagnosis of HIV-1 infection. Additional testing with a newly submitted plasma specimen for HIQNP / HIV-1 RNA Detection and Quantification, Prenatal, Plasma is recommended to verify and confirm the diagnosis of HIV-1 infection prior to initiating antiretroviral treatment.

Positive HIV-1 antibody but indeterminate HIV-2 antibody results indicates the presence of HIV-1 infection, with probable cross-reactivity of HIV-1 antibodies with HIV-2 antigens on the assay strip. Verification of a first-time positive test result is recommended for the diagnosis of HIV-1 infection. Submit a new plasma specimen for detection of HIV-1 RNA (HIQNP / HIV-1 RNA Detection and Quantification, Prenatal, Plasma). However, such result patterns may rarely indicate early HIV-2 infection (ie, HIV-2 coinfection) in HIV-1-infected individuals. For individuals at risk for HIV-2 infection (based on epidemiologic exposure history), a whole blood specimen should be submitted also for FHV2Q / HIV-2 DNA/RNA Qualitative Real-Time PCR.

Indeterminate HIV-1 antibody but negative HIV-2 antibody results suggest either very early HIV-1 infection (in individuals with risk factors) or the presence of nonspecific cross-reactivity between the patients' specimens and
HIV-1 antigens on the assay strip. In this situation, the HIQNP / HIV-1 RNA Detection and Quantification, Prenatal, Plasma reflex test will be performed.

Negative HIV-1 antibody, but indeterminate HIV-2 antibody results, may be due to acute HIV-1 infection or suggests either very early HIV-2 infection (in individuals with risk factors) or presence of nonspecific cross-reactivity between the patients’ specimens and HIV-2 antigens on the assay strip. In this situation, the HIQNP / HIV-1 RNA Detection and Quantification, Prenatal, Plasma reflex test will be performed. If the subsequent HIV-1 RNA test result is negative and patient has known risk factors for HIV-2 infection (based on the patient’s clinical and epidemiologic history), a new whole blood specimen should be submitted for detection of FHV2Q / HIV-2 DNA/RNA Qualitative Real-Time PCR.

Positive results for both HIV-1 and HIV-2 antibodies suggest probable presence of HIV-1 and HIV-2 coinfection. However, such results may be rarely due to: a) HIV-1 infection with HIV-2 antibody cross-reactivity; or b) HIV-2 infection with HIV-1 antibody cross-reactivity (eg, absence of HIV-1 p24 and p31 bands). Verification of a first-time positive test result is recommended for the diagnosis of HIV infection. Based on the patient's clinical and epidemiologic history, a new plasma specimen should be submitted for detection of HIV-1 RNA (HIQNP / HIV-1 RNA Detection and Quantification, Prenatal, Plasma) or a new whole blood specimen for detection of HIV-2 DNA/RNA (FHV2Q / HIV-2 DNA/RNA Qualitative Real-Time PCR).

Indeterminate results for both HIV-1 and HIV-2 antibodies indicate either very early HIV infection (in individuals with risk factors) or the presence of nonspecific cross-reactivity between the patients’ specimens and HIV antigens on the assay strip. Nonspecific cross-reactivity may be due to recent non-HIV infections, hypergammaglobulinemic states, connective tissue disorders, or pregnancy (alloantibodies). In this situation, the HIQNP / HIV-1 RNA Detection and Quantification, Prenatal, Plasma reflex test will be performed.

Negative HIV-1 antibody but positive HIV-2 antibody results indicates the presence of HIV-2 infection. Together with a reactive initial HIV-1/-2 antigen and antibody screening test results, individuals with such results are presumed to have HIV-2 infection. Additional testing with a newly submitted whole blood specimen for FHV2Q / HIV-2 DNA/RNA Qualitative Real-Time PCR is recommended to verify and confirm the diagnosis of HIV-2 infection prior to initiating antiretroviral treatment.

Reactive HIV-1 antibody but positive HIV-2 antibody results usually indicate the presence of HIV-2 infection with HIV-1 antibody cross-reactivity (eg, presence of only HIV-1 gp41 and/or gp160 band). However, such results may be rarely due to HIV-1 and HIV-2 coinfection. Verification of a first-time positive test result is recommended for the diagnosis of HIV-2 infection, by submitting a whole blood specimen for FHV2Q / HIV-2 DNA/RNA Qualitative Real-Time PCR. If the patient is at risk for HIV-1 infection (based on the patient's clinical and epidemiologic history), a plasma specimen should be submitted also for detection of HIV-1 RNA (HIQNP / HIV-1 RNA Detection and Quantification, Prenatal, Plasma).

Indeterminate HIV-1 antibody but positive HIV-2 antibody results indicate the presence of HIV-2 infection, with probable cross-reactivity of HIV-2 antibodies with HIV-1 antigens on the assay strip. Verification of a first-time positive test result is recommended for the diagnosis of HIV-2 infection, by submitting a whole blood specimen for FHV2Q / HIV-2 DNA/RNA Qualitative Real-Time PCR. However, such result patterns may rarely indicate early HIV-1 infection (ie, HIV-1 coinfection) in HIV-2-infected individuals. For individuals at risk for HIV-1 infection, (based on epidemiologic exposure history), a plasma specimen should be submitted also for detection of HIV-1 RNA (HIQNP / HIV-1 RNA Detection and Quantification, Prenatal, Plasma).

The following algorithms are available in Special Instructions:

-HIV Prenatal Testing Algorithm, Including Follow-up of Reactive Rapid Serologic Test Results

-HIV Testing Algorithm (Fourth-Generation Screening Assay), Including Neonatal Testing and Follow-up of Reactive
Rapid Serologic Test Results

Cautions

A negative result for both HIV-1 and HIV-2 antibodies does not rule-out acute HIV infection.

All initially positive supplemental or confirmatory HIV test results should be verified by submitting a second specimen for repeat testing. Such positive HIV test results are required under laws in many states in the United States to be reported to the departments of health of the respective states where the patients reside.

Participation in the recipients of HIV-1 vaccine (eg, participants in HIV-1 vaccine study trials) may develop vaccine-specific antibodies that may cross-react with this test and yield to the vaccine giving a positive, indeterminate, or unreadable HIV-1 antibody result, while they may or may not be infected with HIV-1.

Assay performance characteristics have not been established for the following specimen characteristics:

- Heat-inactivated specimens
- Cadaveric specimens
- Presence of particulate matter

Clinical Reference


Performance

Method Description

The Geenius HIV 1/2 Supplemental Assay cassette contains antibody-binding protein A, which is conjugated to colloidal gold dye particles, and HIV-1 and HIV-2 antigens, which are bound to the membrane solid phase. The sample is applied to the sample and buffer well. After the sample and buffer have migrated onto the test strip, additional buffer is added to the buffer well. The buffer causes the specimens and reagents to flow laterally and facilitates the binding of antibodies to the antigens. In a reactive sample, the antibodies are captured by the antigens
immobilized in the test area.

The protein A-colloidal gold binds to the captured antibodies, causing development of pink or purple lines. When there are no HIV antibodies, there are no pink or purple lines in the test area. The sample continues to migrate through the membrane and a pink or purple line develops in the control (C) area, which contains Protein A. This built-in procedural control provides evidence that the test was performed properly and that the sample and reagents have migrated through the cassette. (Package insert: Geenius HIV 1/2 Supplemental Assay. Bio-Rad Laboratories; 09/2017)

PDF Report
No

Day(s) and Time(s) Test Performed
Monday through Friday; Varies

Analytic Time
1 day

Maximum Laboratory Time
3 days

Specimen Retention Time
14 days

Performing Laboratory Location
Rochester

Fees and Codes

Fees
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer’s instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information
86701

86702

LOINC® Information

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Order Name</th>
<th>Order LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>HVDSP</td>
<td>HIV Ab Differentiation Prenatal, P</td>
<td>89365-1</td>
</tr>
<tr>
<td>Result ID</td>
<td>Test Result Name</td>
<td>Result LOINC Value</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>91952</td>
<td>HIV-1 Ab Differentiation Prenatal, P</td>
<td>68961-2</td>
</tr>
<tr>
<td>91953</td>
<td>HIV-2 Ab Differentiation Prenatal, P</td>
<td>81641-3</td>
</tr>
</tbody>
</table>